Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%.
Adaptimmune Therapeutics Trading Down 4.8 %
NASDAQ:ADAP traded down $0.01 on Monday, reaching $0.28. 2,891,768 shares of the stock traded hands, compared to its average volume of 1,687,464. The firm has a market capitalization of $70.83 million, a price-to-earnings ratio of -1.26 and a beta of 2.52. Adaptimmune Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.65. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The company's 50 day moving average is $0.54 and its 200-day moving average is $0.69.
Analysts Set New Price Targets
A number of research analysts recently commented on ADAP shares. Scotiabank reduced their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday. They issued a "buy" rating for the company. Mizuho decreased their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company lowered their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a report on Friday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $2.18.
Check Out Our Latest Stock Analysis on ADAP
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
